Observational study on the therapeutic management and economic burden of adult patients with moderate to severe plaque psoriasis in France – the POP study
ABSTRACTBackground: Data on the therapeutic management and healthcare cost of moderate to severe psoriasis in France are scarce.Objective: To assess the therapeutic management and economic burden of patients with moderate to severe psoriasis.Setting: This is a retrospective observational study on th...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-12-01
|
| Series: | Journal of Market Access & Health Policy |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/20016689.2023.2270293 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849764603317190656 |
|---|---|
| author | A. P. Villani N. Quiles Tsimaratos A. Crochard A. Gherardi A. Panes A. Schmidt M. Hueber Kollen I. Borget |
| author_facet | A. P. Villani N. Quiles Tsimaratos A. Crochard A. Gherardi A. Panes A. Schmidt M. Hueber Kollen I. Borget |
| author_sort | A. P. Villani |
| collection | DOAJ |
| description | ABSTRACTBackground: Data on the therapeutic management and healthcare cost of moderate to severe psoriasis in France are scarce.Objective: To assess the therapeutic management and economic burden of patients with moderate to severe psoriasis.Setting: This is a retrospective observational study on the Generalist Beneficiaries Sample of the National Health Data System.Patients and outcome measures:Adults with moderate to severe psoriasis (with a topical vitamin D derivative followed by systemic treatment or hospitalization for psoriasis) were included and followed-up from 1 January 2009 to 31 December 2018. Patients were matched to controls without psoriasis. Patients’ characteristics and healthcare cost from the National Health Insurance’s (NHI) perspective were described.Results: Overall, 1,848 and 5,544 adults were included in the psoriatic and control cohorts, respectively. The most frequent treatments were methotrexate (18.5% to 21.4% of patients by year), phototherapy (29.9% in 2010 down to 6.2% in 2018), and acitretin (25.9% in 2010 down to 8.6% in 2018). Overall, 19% of patients used biotherapies. The mean healthcare costs reimbursed by NHI was €5,365/psoriatic patient (including €2,685 potentially attributable to psoriasis), which was twice as high as in controls. In both cohorts, healthcare costs increased over time.Conclusion: Moderate to severe psoriasis healthcare costs are high. [Figure: see text] |
| format | Article |
| id | doaj-art-b6a38eecd2524c6daba736f3b44dd21d |
| institution | DOAJ |
| issn | 2001-6689 |
| language | English |
| publishDate | 2023-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Market Access & Health Policy |
| spelling | doaj-art-b6a38eecd2524c6daba736f3b44dd21d2025-08-20T03:05:06ZengMDPI AGJournal of Market Access & Health Policy2001-66892023-12-0111110.1080/20016689.2023.2270293Observational study on the therapeutic management and economic burden of adult patients with moderate to severe plaque psoriasis in France – the POP studyA. P. Villani0N. Quiles Tsimaratos1A. Crochard2A. Gherardi3A. Panes4A. Schmidt5M. Hueber Kollen6I. Borget7Department of Dermatology, Edouard Herriot Hospital Center, Lyon, FranceDepartment of Dermatology, Saint-Joseph Hospital Center, Marseille, FranceUCB Pharma S.A, Colombes, FranceUCB Pharma S.A, Colombes, FranceHEVA, Lyon, FranceHEVA, Lyon, FranceUCB Pharma S.A, Colombes, FranceBiostatistics and Epidemiology office, Gustave Roussy, Paris-Saclay University, Villejuif, FranceABSTRACTBackground: Data on the therapeutic management and healthcare cost of moderate to severe psoriasis in France are scarce.Objective: To assess the therapeutic management and economic burden of patients with moderate to severe psoriasis.Setting: This is a retrospective observational study on the Generalist Beneficiaries Sample of the National Health Data System.Patients and outcome measures:Adults with moderate to severe psoriasis (with a topical vitamin D derivative followed by systemic treatment or hospitalization for psoriasis) were included and followed-up from 1 January 2009 to 31 December 2018. Patients were matched to controls without psoriasis. Patients’ characteristics and healthcare cost from the National Health Insurance’s (NHI) perspective were described.Results: Overall, 1,848 and 5,544 adults were included in the psoriatic and control cohorts, respectively. The most frequent treatments were methotrexate (18.5% to 21.4% of patients by year), phototherapy (29.9% in 2010 down to 6.2% in 2018), and acitretin (25.9% in 2010 down to 8.6% in 2018). Overall, 19% of patients used biotherapies. The mean healthcare costs reimbursed by NHI was €5,365/psoriatic patient (including €2,685 potentially attributable to psoriasis), which was twice as high as in controls. In both cohorts, healthcare costs increased over time.Conclusion: Moderate to severe psoriasis healthcare costs are high. [Figure: see text]https://www.tandfonline.com/doi/10.1080/20016689.2023.2270293PsoriasisepidemiologycostFrance |
| spellingShingle | A. P. Villani N. Quiles Tsimaratos A. Crochard A. Gherardi A. Panes A. Schmidt M. Hueber Kollen I. Borget Observational study on the therapeutic management and economic burden of adult patients with moderate to severe plaque psoriasis in France – the POP study Journal of Market Access & Health Policy Psoriasis epidemiology cost France |
| title | Observational study on the therapeutic management and economic burden of adult patients with moderate to severe plaque psoriasis in France – the POP study |
| title_full | Observational study on the therapeutic management and economic burden of adult patients with moderate to severe plaque psoriasis in France – the POP study |
| title_fullStr | Observational study on the therapeutic management and economic burden of adult patients with moderate to severe plaque psoriasis in France – the POP study |
| title_full_unstemmed | Observational study on the therapeutic management and economic burden of adult patients with moderate to severe plaque psoriasis in France – the POP study |
| title_short | Observational study on the therapeutic management and economic burden of adult patients with moderate to severe plaque psoriasis in France – the POP study |
| title_sort | observational study on the therapeutic management and economic burden of adult patients with moderate to severe plaque psoriasis in france the pop study |
| topic | Psoriasis epidemiology cost France |
| url | https://www.tandfonline.com/doi/10.1080/20016689.2023.2270293 |
| work_keys_str_mv | AT apvillani observationalstudyonthetherapeuticmanagementandeconomicburdenofadultpatientswithmoderatetosevereplaquepsoriasisinfrancethepopstudy AT nquilestsimaratos observationalstudyonthetherapeuticmanagementandeconomicburdenofadultpatientswithmoderatetosevereplaquepsoriasisinfrancethepopstudy AT acrochard observationalstudyonthetherapeuticmanagementandeconomicburdenofadultpatientswithmoderatetosevereplaquepsoriasisinfrancethepopstudy AT agherardi observationalstudyonthetherapeuticmanagementandeconomicburdenofadultpatientswithmoderatetosevereplaquepsoriasisinfrancethepopstudy AT apanes observationalstudyonthetherapeuticmanagementandeconomicburdenofadultpatientswithmoderatetosevereplaquepsoriasisinfrancethepopstudy AT aschmidt observationalstudyonthetherapeuticmanagementandeconomicburdenofadultpatientswithmoderatetosevereplaquepsoriasisinfrancethepopstudy AT mhueberkollen observationalstudyonthetherapeuticmanagementandeconomicburdenofadultpatientswithmoderatetosevereplaquepsoriasisinfrancethepopstudy AT iborget observationalstudyonthetherapeuticmanagementandeconomicburdenofadultpatientswithmoderatetosevereplaquepsoriasisinfrancethepopstudy |